Japan's drug firms on the move
A homespun elixir
With growth limited at home, Japan’s pharma industry is buying firms abroad
May 20th 2010 | TOKYO
Saturday February 4th 2012
Advertisement
Most commented
- Competition: Help us name our new China blog
- Will the euro survive 2012 intact?
- Banyan: Having it both ways
- China: The paradox of prosperity
- Pollution in China: Man-made and visible from space
- The politics of fairness: Fairly confusing
- Race in Brazil: Affirming a divide
- Tibetans and the Chinese state: No power to pacify
- Debating economic policy: Stimulus, austerity and the weltgeist
- Facebook: A fistful of dollars
Over the past five days
Most recommended
- China: The paradox of prosperity
- The future of teaching: Difference engine: Let the games begin
- Competition: Help us name our new China blog
- Pollution in China: Man-made and visible from space
- Race in Brazil: Affirming a divide
- Technology trade shows: Silicon implants
- Alcohol: Possibly the best travel tip ever
- A presidential cartoon: Riding lessons
- Scandal in Slovakia: The multi-million euro gorilla
- Fernando Henrique Cardoso on Brazil's future: More personal security, less inequality
Over the past seven days
Advertisement
Products & events
Stay informed today and every day
Subscribe to The Economist's free e-mail newsletters and alerts.
Subscribe to The Economist's latest article postings on Twitter
See a selection of The Economist's articles, events, topical videos and debates on Facebook.
Classified ads
Readers' comments
Reader comments are listed below. Comments are currently closed and new comments are no longer being accepted.
Sort:
Ranbaxy is a good company, gave gr8 stock returns. Good for Daichi Sankyo and other Japanese firms, way to go!
Just a correction: the mandatory price cuts are not biannual (twice a year) as you wrote, but biennial (every two years).
I am not usually pedantic but this difference is rather important for pharma in Japan.
Pelle Stolt